IN THE NEWS
In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small molecules for autoimmune disease and cancer against hard-to-drug targets that have been clinically validated, or genetically associated with a disease.
WHAT WE DO
Our proprietary small molecule platform targets accelerates the discovery and development of drugs that correct RNA mis-splicing across a broad range of disease types: